RxDoctor Payments DataLook up a doctor →

Steven Gubin, MD

Cardiovascular Disease · Memphis, TNNPI 1497847867

Payments from drug & device makers

$247,534in general payments, 2019–2025

Across 1,189 payments — averaging $208.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$55K
  • Amgen$46K
  • Johnson & Johnson$38K
  • AstraZeneca$23K
  • Esperion Therapeutics, Inc.$21K
  • Sanofi-aventis U.S. LLC$17K
  • plus $48K from 45 others

What the payments were for

  • Consulting fees$2,0251%
  • Speaking & faculty fees$212,61986%
  • Travel & lodging$7,0713%
  • Food & beverage$25,32010%
  • Education$5000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$247,534 in reported general payments places this provider in the 90th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$1,373,048
Medicare patients
4,741
Services billed
32,489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban829$832,683
Repatha SureclickEvolocumab222$218,472
XareltoRivaroxaban219$210,887
EntrestoSacubitril/Valsartan130$141,674
FarxigaDapagliflozin Propanediol153$131,160
JardianceEmpagliflozin115$116,521
Praluent PenAlirocumab62$41,225
Ezetimibe996$26,871
Rosuvastatin Calcium1,656$22,294
BrilintaTicagrelor22$22,134
Metoprolol Succinate1,088$18,113
LivaloPitavastatin Calcium26$17,085
Ranolazine ErRanolazine106$14,458
VerquvoVericiguat13$14,089
Nebivolol Hcl230$13,939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$3,554$832,683829 claims
Johnson & JohnsonXarelto$37,731$210,887219 claims
AstraZenecaFarxiga, Brilinta$23,010$153,294175 claims
NovartisEntresto$1,823$141,674130 claims
Boehringer IngelheimJardiance$54,753$116,521115 claims
Kowa Pharmaceuticals America, Inc.Livalo, Bystolic$45$22,95545 claims
MerckVerquvo$726$14,08913 claims
Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi$69$11,69331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →